問卷

TPIDB > Search Result

Search Result

篩選

List

21Cases

2025-11-01 - 2030-12-31

Phase III

Active
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
  • Condition/Disease

    Prostatic Neoplasms, Castration-Resistant

  • Test Drug

    靜脈輸注液 靜脈輸注液 錠劑

Participate Sites
5Sites

Recruiting5Sites

2025-09-15 - 2030-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-11-01 - 2031-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-08-01 - 2035-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2029-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-12-30 - 2027-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-09-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-07-14 - 2026-11-30

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2025-04-15 - 2032-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-05-06 - 2033-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3